Changing burden of gastrointestinal disease {#sec1}
===========================================

In 2004, in the United States, there were 72 million presentations with a primary diagnosis of a digestive disease and 104 million presentations with combined gastrointestinal (GI) tract diseases and other diseases ([Table 1](#tbl1){ref-type="table"} ).[@bib1] It was also found that those who are older tend to have more GI problems, there was no difference in the rates of digestive disease between the African Americans and the whites, and women were 20% more likely to present than men with digestive diseases. Thus, more than one-third (35%) of all presentations are for digestive diseases. In 2009, in the United States, the cancer statistics revealed 275,720 new cases of GI cancer, with colorectal and pancreatic cancer in the top 10 for both men and women.[@bib2] There were 135,830 deaths due to GI cancer, with colorectal, pancreatic, hepatic, and esophageal cancers in the top 10 for both men and women, except for esophageal cancer, which was only listed for men ([Fig. 1](#fig1){ref-type="fig"} ).[@bib2] Furthermore, 2 of these 3 cancers that have an increasing mortality were GI tract cancers for both genders, with esophageal and hepatic cancers among men and pancreatic and hepatic cancers among women. Worldwide the rates of digestive diseases are staggering.Table 1Burden of selected digestive diseases in the United States, 2004Digestive DiseaseDeaths, Underlying Cause[a](#tblfn1){ref-type="table-fn"}Years of Potential Life Lost to Age 75 Years[a](#tblfn1){ref-type="table-fn"}Ambulatory Care Visits, All-Listed Diagnoses[b](#tblfn2){ref-type="table-fn"}Hospital Discharges, All-Listed Diagnoses[c](#tblfn3){ref-type="table-fn"}All Digestive Diseases236,1642,007,500104,790,00013,533,000All Digestive Cancers135,107945,2004,198,000726,000 Colorectal Cancer53,226333,0002,589,000255,000 Pancreatic Cancer31,800206,800415,00068,000 Esophageal Cancer13,667113,800372,00044,000 Gastric Cancer11,25384,200141,00031,000 Primary Liver Cancer632372,40063,00033,000 Bile Duct Cancer495432,900---17,000 Gall Bladder Cancer193910,900---6000 Cancer of the Small Intestine11159300---9000Liver Disease36,090559,1002,398,000759,000All Viral Hepatitis5393101,8003,510,000475,000 Hepatitis C459587,5002,747,000419,000 Hepatitis B64511,800729,00069,000 Hepatitis A58800---10,000GI Infections439612,8002,365,000[450,000]{.smallcaps}Peptic Ulcer Disease369219,7001,473,000489,000Pancreatitis348042,800881,000454,000Diverticular Disease337286003,269,000815,000Abdominal Wall Hernia117269004,787,000372,000Gastroesophageal Reflux Disease1150600018,342,0003,189,000Gallstones109244001,836,000622,000All Inflammatory Bowel Disease93391001,892,000221,000 Crohn Disease62270001,176,000141,000 Ulcerative Colitis3112000716,00082,000Appendicitis4535000782,000325,000All Functional Intestinal Disorders423250011,648,0001,241,000 Chronic Constipation1379006,306,000700,000 Irritable Bowel Syndrome2003,054,000212,000Hemorrhoids142003,275,000306,000[^1][^2][^3]*Data from* Everhart JE, editor. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008; NIH Publication No. 09--6443; p. 6--7.Fig. 1The 10 leading cancer types among the estimated new cancer cases and deaths, by sex, in the United States in 2009.(*From* Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225--49; with permission.)

From 1979 to 1989, in the United States, a decrease was observed in the ambulatory care visits and hospital discharges for digestive diseases. These rates remained constant between 1990 and 1999, until 2000 when the rates climbed dramatically and was still increasing in 2004 ([Fig. 2](#fig2){ref-type="fig"} ).[@bib1] During this period, substantial increases in the prevalence were observed for certain GI tract diseases, including gastroesophageal reflux disease (GERD) with an increase of 376 per 100,000 population, hepatitis C with 79 per 100,000 population, chronic constipation with 62 per 100,000 population, intestinal infections with 41 per 100,000 population, and pancreatitis with 23 per 100,000 population.[@bib1] Fig. 2For all digestive diseases, age-adjusted rates of ambulatory care visits and hospital discharges with all-listed diagnoses in the United States from 1979 to 2004.(*From* Everhart JE, editor. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2008; NIH Publication No. 09--6443 p. 6--7.

The prevalence of digestive diseases around the world is enormous and varies from country to country ([Table 2](#tbl2){ref-type="table"} ). Worldwide there has been a dynamic shift in the epidemiology of GI tract diseases, with some diseases such as peptic ulcer decreasing dramatically since the discovery of *Helicobacter pylori* infection and a larger number of conditions increasing, such as GERD, nonalcoholic fatty liver disease, diverticular disease, Barrett esophagus, cholelithiasis, alcoholic liver disease, hepatitis C, chronic pancreatitis, esophageal cancer and colorectal cancer.[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] In conjunction with this increasing incidence of digestive diseases are the re-emergence of certain infectious agents ([Box 1](#tbox1){ref-type="boxed-text"} ) (eg, cholera) and the identification of new agents (eg, *H pylori*, *Laribacter*, *Campylobacter concisus*), which are associated with GI tract diseases.[@bib9] Since the discovery of *H pylori* there has been an enormous interest in the relationship between microorganisms and GI tract diseases, including cancers.Table 2Estimates of digestive disease burden around the worldCountry/RegionExtrapolated PrevalencePopulation Estimated UsedDigestive Diseases in North America (Extrapolated Statistics)United States of America64,776,924293,655,405[a](#tblfn4){ref-type="table-fn"}Canada7,170,85432,507,874[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in Europe (Extrapolated Statistics)Austria1,803,2568,174,7622Belgium2,282,70710,348,276[b](#tblfn5){ref-type="table-fn"}Britain (United Kingdom)13,295,00860,270,708 for UK[b](#tblfn5){ref-type="table-fn"}Czech Republic274,89210,246,178[b](#tblfn5){ref-type="table-fn"}Denmark1,194,1305,413,392[b](#tblfn5){ref-type="table-fn"}Finland1,150,2595,214,512[b](#tblfn5){ref-type="table-fn"}France13,328,86960,424,213[b](#tblfn5){ref-type="table-fn"}Greece2,348,71910,647,529[b](#tblfn5){ref-type="table-fn"}Germany18,181,89882,424,609[b](#tblfn5){ref-type="table-fn"}Iceland64,845293,966[b](#tblfn5){ref-type="table-fn"}Hungary2,213,02310,032,375[b](#tblfn5){ref-type="table-fn"}Liechtenstein737533,436[b](#tblfn5){ref-type="table-fn"}Ireland875,6373,969,558[b](#tblfn5){ref-type="table-fn"}Italy12,806,79558,057,477[b](#tblfn5){ref-type="table-fn"}Luxembourg102,063462,690[b](#tblfn5){ref-type="table-fn"}Monaco711832,270[b](#tblfn5){ref-type="table-fn"}Netherlands (Holland)3,599,60216,318,199[b](#tblfn5){ref-type="table-fn"}Poland8,520,51738,626,349[b](#tblfn5){ref-type="table-fn"}Portugal2,321,50210,524,145[b](#tblfn5){ref-type="table-fn"}Spain8,885,46540,280,780[b](#tblfn5){ref-type="table-fn"}Sweden1,982,2948,986,400[b](#tblfn5){ref-type="table-fn"}Switzerland1,643,5737,450,867[b](#tblfn5){ref-type="table-fn"}United Kingdom13,295,00860,270,708[b](#tblfn5){ref-type="table-fn"}Wales643,6762,918,000[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in the Balkans (Extrapolated Statistics)Albania781,9423,544,808[b](#tblfn5){ref-type="table-fn"}Bosnia and Herzegovina89,913407,608[b](#tblfn5){ref-type="table-fn"}Croatia991,9564,496,869[b](#tblfn5){ref-type="table-fn"}Macedonia450,0182,040,085[b](#tblfn5){ref-type="table-fn"}Serbia and Montenegro2,388,06610,825,900[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in Asia (Extrapolated Statistics)Bangladesh31,178,044141,340,476[b](#tblfn5){ref-type="table-fn"}Bhutan482,1102,185,569[b](#tblfn5){ref-type="table-fn"}China286,510,4931,298,847,624[b](#tblfn5){ref-type="table-fn"}East Timor224,8341,019,252[b](#tblfn5){ref-type="table-fn"}Hong Kong SAR1,512,1596,855,125[b](#tblfn5){ref-type="table-fn"}India234,942,0361,065,070,607[b](#tblfn5){ref-type="table-fn"}Indonesia52,599,913238,452,952[b](#tblfn5){ref-type="table-fn"}Japan28,088,161127,333,002[b](#tblfn5){ref-type="table-fn"}Laos1,338,5556,068,117[b](#tblfn5){ref-type="table-fn"}Macau SAR98,224445,286[b](#tblfn5){ref-type="table-fn"}Malaysia5,188,78223,522,482[b](#tblfn5){ref-type="table-fn"}Mongolia606,9072,751,314[b](#tblfn5){ref-type="table-fn"}Philippines19,023,90286,241,697[b](#tblfn5){ref-type="table-fn"}Papua New Guinea1,195,6495,420,280[b](#tblfn5){ref-type="table-fn"}Vietnam18,234,44082,662,800[b](#tblfn5){ref-type="table-fn"}Singapore960,4174,353,893[b](#tblfn5){ref-type="table-fn"}Pakistan35,116,837159,196,336[b](#tblfn5){ref-type="table-fn"}North Korea5,006,81222,697,553[b](#tblfn5){ref-type="table-fn"}South Korea10,639,79948,233,760[b](#tblfn5){ref-type="table-fn"}Sri Lanka4,390,84519,905,165[b](#tblfn5){ref-type="table-fn"}Taiwan5,018,34622,749,838[b](#tblfn5){ref-type="table-fn"}Thailand14,308,57064,865,523[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in Eastern Europe (Extrapolated Statistics)Azerbaijan1,735,6737,868,385[b](#tblfn5){ref-type="table-fn"}Belarus2,274,37910,310,520[b](#tblfn5){ref-type="table-fn"}Bulgaria1,658,3767,517,973[b](#tblfn5){ref-type="table-fn"}Estonia295,9551,341,664[b](#tblfn5){ref-type="table-fn"}Georgia1,035,4174,693,892[b](#tblfn5){ref-type="table-fn"}Kazakhstan3,340,52215,143,704[b](#tblfn5){ref-type="table-fn"}Latvia508,7432,306,306[b](#tblfn5){ref-type="table-fn"}Lithuania795,8603,607,899[b](#tblfn5){ref-type="table-fn"}Romania4,931,37122,355,551[b](#tblfn5){ref-type="table-fn"}Russia31,758,982143,974,059[b](#tblfn5){ref-type="table-fn"}Slovakia1,196,3755,423,567[b](#tblfn5){ref-type="table-fn"}Slovenia443,7072,011,473[b](#tblfn5){ref-type="table-fn"}Tajikistan1,546,6667,011,556[b](#tblfn5){ref-type="table-fn"}Ukraine10,529,13447,732,079[b](#tblfn5){ref-type="table-fn"}Uzbekistan5,825,82626,410,416[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in Australasia and Southern Pacific (Extrapolated Statistics)Australia4,392,60519,913,144[b](#tblfn5){ref-type="table-fn"}New Zealand880,9893,993,817[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in the Middle East (Extrapolated Statistics)Afghanistan6,289,78128,513,677[b](#tblfn5){ref-type="table-fn"}Egypt16,790,60676,117,421[b](#tblfn5){ref-type="table-fn"}Gaza Strip292,2771,324,991[b](#tblfn5){ref-type="table-fn"}Iran14,890,41267,503,205[b](#tblfn5){ref-type="table-fn"}Iraq5,597,35825,374,691[b](#tblfn5){ref-type="table-fn"}Israel1,367,4286,199,008[b](#tblfn5){ref-type="table-fn"}Jordan1,237,7655,611,202[b](#tblfn5){ref-type="table-fn"}Kuwait497,9882,257,549[b](#tblfn5){ref-type="table-fn"}Lebanon833,2093,777,218[b](#tblfn5){ref-type="table-fn"}Libya1,242,2615,631,585[b](#tblfn5){ref-type="table-fn"}Saudi Arabia5,690,28025,795,938[b](#tblfn5){ref-type="table-fn"}Syria3,974,31018,016,874[b](#tblfn5){ref-type="table-fn"}Turkey15,197,18768,893,918[b](#tblfn5){ref-type="table-fn"}United Arab Emirates556,7452,523,915[b](#tblfn5){ref-type="table-fn"}West Bank509,8242,311,204[b](#tblfn5){ref-type="table-fn"}Yemen4,417,24920,024,867[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in South America (Extrapolated Statistics)Belize60,208272,945[b](#tblfn5){ref-type="table-fn"}Brazil40,610,537184,101,109[b](#tblfn5){ref-type="table-fn"}Chile3,490,57815,823,957[b](#tblfn5){ref-type="table-fn"}Colombia9,333,25842,310,775[b](#tblfn5){ref-type="table-fn"}Guatemala3,150,13114,280,596[b](#tblfn5){ref-type="table-fn"}Mexico23,152,850104,959,594[b](#tblfn5){ref-type="table-fn"}Nicaragua1,182,2995,359,759[b](#tblfn5){ref-type="table-fn"}Paraguay1,365,7426,191,368[b](#tblfn5){ref-type="table-fn"}Peru6,075,94927,544,305[b](#tblfn5){ref-type="table-fn"}Puerto Rico859,8443,897,960[b](#tblfn5){ref-type="table-fn"}Venezuela5,518,54125,017,387[b](#tblfn5){ref-type="table-fn"}Digestive Diseases in Africa (Extrapolated Statistics)Angola2,421,73910,978,552[b](#tblfn5){ref-type="table-fn"}Botswana361,5951,639,231[b](#tblfn5){ref-type="table-fn"}Central African Republic825,5473,742,482[b](#tblfn5){ref-type="table-fn"}Chad2,104,0909,538,544[b](#tblfn5){ref-type="table-fn"}Congo Brazzaville661,3322,998,040[b](#tblfn5){ref-type="table-fn"}Congo Kinshasa12,864,05058,317,030[b](#tblfn5){ref-type="table-fn"}Ethiopia15,736,00771,336,571[b](#tblfn5){ref-type="table-fn"}Ghana4,578,75620,757,032[b](#tblfn5){ref-type="table-fn"}Kenya7,275,46432,982,109[b](#tblfn5){ref-type="table-fn"}Liberia747,9343,390,635[b](#tblfn5){ref-type="table-fn"}Niger2,506,00011,360,538[b](#tblfn5){ref-type="table-fn"}Nigeria3,915,519125,750,356[b](#tblfn5){ref-type="table-fn"}Rwanda1,817,3548,238,673[b](#tblfn5){ref-type="table-fn"}Senegal2,393,85510,852,147[b](#tblfn5){ref-type="table-fn"}Sierra Leone1,297,9165,883,889[b](#tblfn5){ref-type="table-fn"}Somalia1,831,8978,304,601[b](#tblfn5){ref-type="table-fn"}Sudan8,635,62339,148,162[b](#tblfn5){ref-type="table-fn"}South Africa9,804,80944,448,470[b](#tblfn5){ref-type="table-fn"}Swaziland257,9201,169,241[b](#tblfn5){ref-type="table-fn"}Tanzania7,956,79336,070,799[b](#tblfn5){ref-type="table-fn"}Uganda5,821,38026,390,258[b](#tblfn5){ref-type="table-fn"}Zambia2,432,13711,025,690[b](#tblfn5){ref-type="table-fn"}Zimbabwe809,96912,671,860[b](#tblfn5){ref-type="table-fn"}[^4][^5][^6]Box 1List of the National Institute of Allergy and Infectious Diseases on emerging and re-emerging diseasesGroup I: pathogens newly recognized in the past 2 decadesAcanthamebiasisAustralian bat Lyssavirus*Babesia*, atypical*Bartonella henselae*Ehrlichiosis*Encephalitozoon cuniculiEncephalitozoon hellemEnterocytozoon bieneusiH pyloriHendra* or equine *morbillivirus*Hepatitis CHepatitis EHuman herpesvirus 8Human herpesvirus 6Lyme borreliosisParvovirus B19 Group II: re-emerging pathogensEnterovirus 71*Clostridium difficile*Mumps virus*Streptococcus*, group A*Staphylococcus aureus* Group III: Agents with bioterrorism potentialNational Institute of Allergy and Infectious Diseases (NIAID): category A*Bacillus anthracis* (anthrax)*Clostridium botulinum* toxin (botulism)*Yersinia pestis* (plague)Variola major (smallpox) and other related poxviruses*Francisella tularensis* (tularemia)Viral hemorrhagic feversArenaviruses: lymphocytic choriomeningitis virus, Junin virus, Machupo virus, Guanarito virus, Lassa feverBunyaviruses: Hantaviruses, Rift Valley fever, Flaviviruses, dengue virusFiloviruses: Ebola, MarburgNIAID: category B*Burkholderia pseudomalleiCoxiella burnetii* (Q fever)*Brucella* species (brucellosis)*Burkholderia mallei* (glanders)*Chlamydia psittaci* (psittacosis)Ricin toxin (from *Ricinus communis*)Epsilon toxin of *Clostridium perfringensStaphylococcus* enterotoxin BTyphus fever (*Rickettsia prowazekii*)Food- and waterborne pathogensDiarrheagenic *Escherichia coli*Pathogenic vibrios*Shigella* species*SalmonellaListeria monocytogenesCampylobacter jejuniYersinia enterocolitica*Viruses (Caliciviruses, Hepatitis A)Protozoa: *Cryptosporidium parvum*, *Cyclospora cayetanensis*, *Giardia lamblia*, *Entamoeba histolytica*, *Toxoplasma*FungiMicrosporidiaAdditional viral encephalitides: West Nile virus, La Crosse virus, California encephalitis virus, Venezuelan equine encephalitis virus, Eastern equine encephalitis virus, Western equine encephalitis, Japanese encephalitis virus, Kyasanur forest virusNIAID: category CEmerging infectious disease threats such as Nipah virus and additional hantavirusesNIAID priority areasTick-borne hemorrhagic fever viruses: Crimean-Congo hemorrhagic fever virusTick-borne encephalitis virusesYellow feverMultidrug-resistant tuberculosisInfluenzaOther rickettsiasRabiesPrionsChikungunya virusSevere acute respiratory syndrome--associated coronavirusAntimicrobial resistance, excluding research on sexually transmitted organismsResearch on mechanisms of antimicrobial resistanceStudies of the emergence and/or spread of antimicrobial resistance genes within pathogen populationsStudies of the emergence and/or spread of antimicrobial-resistant pathogens in human populationsResearch on therapeutic approaches that target resistance mechanismsModification of existing antimicrobials to overcome emergent resistanceAntimicrobial research, as related to engineered threats and naturally occurring drug-resistant pathogens, focused on the development of broad-spectrum antimicrobialsInnate immunity, defined as the study of nonadaptive immune mechanisms that recognize, and respond to, microorganisms, microbial products, and antigens*Coccidioides immitisCoccidioides posadasii*

Cause-and-effect issues {#sec2}
=======================

One of the main issues associated with infections and disease is determining the relationship of the cause and effect. The landmark article by Sir Austin Bradford Hill in 1965 titled The environment and disease: association or causation? became widely known as the Bradford Hill's criteria.[@bib10] There were 8 criteria that were required to be met to determine a cause-and-effect relationship ([Box 2](#tbox2){ref-type="boxed-text"} ). It is usually difficult to meet all these criteria, particularly when trying to find the cause-and-effect relationships between organisms in the small intestine or colon because of the large number of organisms living in these environments. Even for *H pylori* infection and the relationship with gastric cancer, although it is currently the only bacterium classified as a class I carcinogen, the evidence supporting this relationship is not complete in terms of Bradford Hill's criteria.Box 2Bradford Hill's criteria for causalityConsistency: The association is consistent when results are replicated in studies in different settings using different methods.Strength: This is defined by the size of the risk as measured by appropriate statistical tests.Specificity: This is established when a single putative cause produces a specific effect.Dose-response relationship: An increasing level of exposure (in amount and/or time) increases the risk.Temporal relationship: Exposure always precedes the outcome.Biologic plausibility: The association agrees with currently accepted understanding of pathobiologic processes. This criterion should be applied with caution.Coherence: The association should be compatible with existing theory and knowledge.Experiment: The condition can be altered by an appropriate experimental regimen. Experiment is possibly the most important support for a causal relationship.

Organisms associated with GI tract diseases {#sec3}
===========================================

There are a large number of organisms believed to be responsible for diseases of the digestive system. Some of these organisms are true pathogens, whereas others are merely commensal in nature and are unlikely to ever produce any pathologic condition. [Table 3](#tbl3){ref-type="table"} shows the various types of microbes that are associated with diseases of the GI tract covered in this issue; it is by no means all-inclusive but provides the current magnitude of an ever-increasing field of research. At present, some of these diseases are only associated with a single group of organisms (eg, irritable bowel syndrome), whereas other diseases are affected by all groups of organisms (eg, appendicitis).Table 3Organisms associated with GI tract disease in humansGI Tract DiseaseBacteriaVirusParasiteFungiEsophageal Cancerα-hemolytic streptococcus, β-hemolytic streptococcus, *Bacteroides fragilis*, *Bacteroides melaninogenicus*, *Bacteroides* sp, *Clostridium* sp, coagulase-negative *Staphylococcus*, *Corynebacterium* sp, *Escherichia coli*, *Fusobacteria* sp, *Haemophilus influenzae*, *Lactobacillus* sp, *Neisseria catarrhalis*, nonhemolytic streptococcus, *Peptococcus*, *Pneumococcus*, *Proteus mirabilis*, *Staphylococcus albus*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus viridans*, *Candida albicans Mycobacterium avium, Mycobacterium tuberculosis*Cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Varicella-zoster virusCryptosporidiumHistoplasma capsulatum,Gastric Cancer*H pylori*Epstein-Barr virus------Cholangiocarcinoma---Hepatitis C virus, Hepatitis B virus*Clonorchis sinensis*, *Opistochus vivarini*---Gall Bladder Disease*E coli*, *H pylori*, *Helicobacter* sp, Enterobacteriaceae, Leptospira, *Salmonella enteritidis*, *Salmonella typhi*, *Staphylococcus aureus*, *Micrococcus* spCytomegalovirus, Epstein-Barr virus, Dengue virus*C sinensis*, *O vivarini, Ascaris lumbricoides*, *Dolosigranulum pigrumActinomyces* sp, *Candida* sp,Hepatocellular Carcinoma---Hepatitis B virus, Hepatitis C virus------Acute Pancreatitis*Mycoplasma pneumoniae*, *S typhi*, *Leptospira*, *Yersinia enterocolitica*, *Yersinia pseudotuberculosis*, *Campylobacter jejuni*, *M tuberculosis*, *M avium*, *Legionella* sp, *Brucellosis*, *Actinomyces*, *Nocardia*Measles virus, Coxsackie B virus, hepatitis B virus, Cytomegalovirus, herpes simplex virus, varicella virus, human immunodeficiency virus, Epstein-Barr virus, vaccinia, rubella, adenovirus*A lumbricoides, Echinococcus granulosusAspergillus* sp, *Cryptococcus neoformans*, *Coccidioides immitis*, *Paracoccidioides brasiliensis*, *Histoplasma capsulatum*, *Pneumocystis carinii*Small Intestinal Bacterial Overgrowth*Streptococcus* sp, *E coli*, *Staphylococcus* sp, *Micrococcus* sp, *Klebsiella* sp, *Methanobrevibacter smithii*, *Bacteroides* sp, *Firmicutes* sp---------Irritable Bowel Syndrome*Salmonella* sp, *Campylobacter* sp, *Shigella* sp, Enterobacteriaceae, Clostridia---------Inflammatory Bowel Disease*E coli*, *M avium*, *Streptococcus* sp, Clostridia, Actinobacteria, Proteobacteria, *Clostridium leptum*, *Faecalibacterium prausnitzii*, *Bacteroides*, Fusobacteria---------Appendicitis*Y enterocolitica, Y pseudotuberculosis, Actinomyces israelii*, *Mycobacterium*, *C jejuni*, *Clostridium difficile*, *Salmonella* sp, *B fragilis*Adenovirus, cytomegalovirus, measles virus (rubeola virus)*A lumbricoides, Enterobius vermicularis*, *Strongyloides stercoralis*, *Schistosomiasis haematobium*, *Entamoeba histolytica*, *Trichuris* spMucormycosis, histoplasma capsulatumColorectal Cancer*Helicobacter hepaticus*, *Enterococcus faecalis*, *Streptococcus bovis*, *H pylori*, *Clostridium septicum*, *E coli*, *Streptococcus sanguis*, *Streptococcus salivarius*Human papillomavirus, JC virus, Epstein-Barr virus, cytomegalovirus------

Future challenges {#sec4}
=================

There are a variety of methodological and technical issues related to infectious agents and their role in digestive diseases. For diseases of the colon, the major limitation remains the inability to completely identify these organisms. Identification of bacteria was mainly conducted using culture-based methods. Now, the focus in identification of bacteria is increasingly based on using molecular techniques. Many of these techniques allow the detection and identification of viable but nonculturable cells that are metabolically active but not reproducing. Gene sequencing using single-stranded RNA has been a key method in being able to elucidate multitudes of organisms that remain unknown. At present, there are approximately 9000 bacterial species, and this number is estimated as just the tip of the iceberg. The development of molecular methods offers great promise not only in research and development but also in the diagnostic setting (eg, stool samples) ([Table 4](#tbl4){ref-type="table"} ).[@bib11], [@bib12] Clearly, metagenomics, in which genetic material is directly retrieved from environmental sources, will play a critical role in the future development of determining infectious agents of the GI tract. The use of high-throughput technology has already produced important findings in relation to the GI tract microflora, including the differences between adults and children, with numerous uncultured organisms being the crux of the normal human adult gut flora which remain stable but other organisms change depending on environmental and genetic factors, whereas in infants there appear to be a constant transformation of organisms over time ([Figs. 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} ).[@bib11] There have been several new detection methods developed, with some of these using nanoscale electrochemical detectors and others using DNA sensors (extrachromosomal DNA).[@bib13] The use of stable-isotope probing is also being investigated, but even this technique has limitations.[@bib14] Although these technologies are increasing the understanding of the gut microflora, there remains large gaps of knowledge regarding the metabolic functions of these organisms and the relationship they have with human GI disease. These will be extremely fruitful areas of research and development in the coming years.Table 4Automatic nucleic acid extraction methods from bacteriaInstrumentMethodNumber of SamplesTime RequiredABI PRISM 6100 nucleic acid PrepStation (Applied Biosystems)Silica membrane bind/elute protocols with vacuum processing (RNA and DNA)Up to 9630 minABI PRISM 6700 automated nucleic acid workstation (Applied Biosystems)Silica membrane bind/elute protocols with vacuum processing (RNA and DNA)Up to 9690 minBioRobot EZ1 workstation (QIAGEN)Silica membrane bind/elute protocols using magnetic-particle handling (RNA and DNA)1--615--20 miniPrep Purification Instrument (Invitrogen)Based on a unique, ionizable nucleic acid-binding ligand whose charge can be switched based on the pH of the surrounding medium (DNA)Up to 1218 minKingFisher ML/96 (Thermo Scientific)Silica membrane bind/elute protocols using magnetic-particle handling (RNA and DNA)1--9620--30 minMagNA pure compact/LC (Roche Applied Science)Silica membrane bind/elute protocols using magnetic-particle handling (RNA and DNA)1--3215--40 minMaxwell 16 Instrument (Promega)Silica membrane bind/elute protocols using magnetic-particle handling (RNA and DNA)Up to 1630 minNucliSens miniMAG (BioMérieux)Silica membrane bind/elute protocols using magnetic-particle handling (RNA and DNA)Up to 1245 minQIAcube (QIAGEN)Silica membrane bind/elute protocols with built in centrifuge (RNA and DNA)Up to 1260 min, user-developed protocolsX-Tractor Gene RNA/DNA Extraction System (Corbett Life Science)Silica membrane bind/elute protocols with vacuum processing (RNA and DNA)8--961 h*Data from* Barken KB, Haagensen JA, Tolker-Nielsen T. Advances in nucleic acid-based diagnostics of bacterial infections. Clin Chim Acta 2007;384:1--11.Fig. 3High-throughput analysis of human GI tract microbiota via brute force sequencing and phylogenetic microarray analysis. SSU rRNA, small subunit ribosomal RNA.(*From* Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008;57:1605--15; with permission.)Fig. 4Metagenomics and other community-based "omics" approaches. SSU rRNA, small subunit ribosomal RNA.(*From* Zoetendal EG, Rajilic-Stojanovic M, de Vos WM, High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008;57:1605--15, with permission.)
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